in a large amount due to the rapid increasing population who underwent NIPT. The 7 1 discordance between cell-free DNA (cfDNA) and fetal karyotype could be a major 7 2 concern of NIPT technic, which could be attributed to various factors including 7 3 confined placental mosaics, co-twin demise, maternal chromosomal mosaics and 7 4 maternal malignancy (Bianchi et al., 2015) .
5
Of them, maternal malignancy has drawn more and more attention, due to its fatal been reported on other cancer types.
8 5
In the current report, we presented two cases of aberrant chromosomal aneuploidies 8 6
unraveled by NIPT subsequently diagnosed with dysgerminoma and gastric cancer, respectively. These case reports supported the potential of applying NIPT to 8 8
pre-symptomatic detection of malignant tumors in pregnant women in the future. Ten millimeters of maternal peripheral blood were collected in Cell Free DNA BCT ® 9 3 blood collection tube and was processed within 4 days of collection. Details of the 9 4
NIPT method, also called Non-invasive fetal trisomy test (NIFTY), have been was sequenced and the data generated was analyzed using the bioinformatics 1 0 0 algorithm to detect fetal chromosomal aneuploidy and large deletion/duplication, as Somatic Copy number analysis for this tumor was performed using MIP array data were processed and normalized by Affymetrix as previously described with However, the right ovarian cyst with internal flow enlarged gradually as gestational 1 2 9
week and fetal MRI revealed that an 8.7x7.9x6.0cm lobulated soft tissue mass at right 1 3 0 adnexa with engorged regional collateral vessels noted with diffusion restriction 1 3 1 (Figure 1 A and B) . At 36 weeks gestational age, patients underwent a cesarean appendix ( Figure 1C and D) . Thereafter, the patient received 6-course of After knowing concurrent pregnancy and dysgerminoma in this patient, we 1 4 0 re-examined the NIPT results and found multiple aneuploidies in the blood DNA, 1 4 1 which was the main reason of NIPT failure (Figure 2A ).
4 2
To study the resource of genetic variations found in NIPT, MIP array technology performed. We found the concordance of chromosome alterations between maternal 1 4 5 plasma DNA and tumor tissue (Figure 2A and B) , such as gain of whole short arm of Those results suggested that tumor cfDNA contributed to the aberrant NIPT results. To further validate this result, another cfDNA test was conducted after the surgery and week of diagnosis, she died of gastric cancer. Due to lack of cancer samples, no were observed, providing further evidence that NIPT test is able to detect the tumor 1 6 8 ctDNA in maternal blood. Vandenbroucke , et al., 2015; Bianchi et al., 2015; Osborne et al., 2013) . Although undergoing NIPT screening, our report is the first to reveal the association between 1 7 6 maternal cancer and aberrant NIPT results in Asian population. In this study, two 1 7 7
Asian pregnant women showed aberrant NIPT results and subsequently diagnosed the whole genome. According to previous study (Bianchi et al., 2015) , patients with 1 8 0 multiple aneuploidies are strongly associated to maternal cancer, which is also abnormal NIPT results is much lower, which is the case in our study. So far, only two 1 9 7 cases of abnormal NIPT results were confirmed with concurrent maternal 1 9 8 malignancies, despite the large number of NIPT tests conducted in Asia. One possible 1 9 9
explanation is that present NIPT products focus mainly on the abnormal trisomy-13, 2 0 0 18, and 21, multiple aneuploidies were shown to be frequently correlated with 
